Despite the efforts for the management of hyperglycemia and hypertension using current therapies, such as angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) [3,4], the risk of DN progression has still not been reduced. Here, ACE is linked to Hyperglycemia.